Today: 9 June 2026
Browse Category

NSE:AUSFB 17 November 2025 - 27 December 2025

Bombay Stock Exchange Today: Sensex Slips on Year-End Profit-Taking as BSE Bankex Revamp Kicks In

Bombay Stock Exchange Today: Sensex Slips on Year-End Profit-Taking as BSE Bankex Revamp Kicks In

The S&P BSE Sensex fell 0.43% to 85,041.45 and the NSE Nifty 50 dropped 0.38% to 26,042.3 in thin year-end trading Friday, but both indexes still posted modest weekly gains. BSE Bankex expanded to 14 stocks on December 26, adding Canara Bank, AU Small Finance Bank, Punjab National Bank, and Union Bank of India, with a new 45% cap on the top three constituents’ combined weight.
27 December 2025
····
Top Stock Gainers in India Today (December 10, 2025): Highway Infrastructure, Meesho, Sammaan Capital, AU SFB and Hindustan Zinc in Focus

Top Stock Gainers in India Today (December 10, 2025): Highway Infrastructure, Meesho, Sammaan Capital, AU SFB and Hindustan Zinc in Focus

The BSE Sensex traded near 84,645, down 0.03%, and the Nifty 50 was flat at 25,839 by midday Wednesday. Eicher Motors rose 1.7%, HDFC Life 1.26%, and Hindalco 1.24% among Nifty 50 gainers, while metals and auto stocks outperformed. Highway Infrastructure jumped nearly 13% after winning a ₹329-crore NHAI contract. Broader markets lagged, with mid- and small-cap indices slipping.
10 December 2025
··
Stock Market Today: Nifty 50 Closes Above 26,000 on NSE, Bank Nifty Hits Record High – Full Round‑Up for 17 November 2025

Stock Market Today: Nifty 50 Closes Above 26,000 on NSE, Bank Nifty Hits Record High – Full Round‑Up for 17 November 2025

The Nifty 50 closed above 26,000 for the first time since October, ending at 26,013.45, up 0.40%. The Sensex finished at 84,950.95, gaining 388 points. Bank Nifty hit an intraday record high near 59,001.55, with both public and private banks advancing. NSE-listed companies’ total market capitalisation reached nearly ₹474.3 lakh crore ($5.35 trillion).
17 November 2025
····

Stock Market Today

  • Amgen (AMGN) Stock Analysis: Is It Still Undervalued After Strong Multi-Year Gains?
    June 9, 2026, 9:58 AM EDT. Amgen's stock has appreciated by 68.7% over five years, closing recently at $345.73. Despite robust share price gains, a Discounted Cash Flow (DCF) analysis indicates the stock is 48.3% undervalued, with an intrinsic value estimate of $668.86 per share based on projected future cash flows. The model uses Free Cash Flow to Equity, forecasting growth through 2035. Amgen trades at a price-to-earnings (P/E) ratio of 23.92x, reflecting market expectations for earnings and risk. Investors are reassessing Amgen's fair value amid its steady growth and large-cap biotechnology sector position, as it delivers a one-year return of 21.4%, slightly lagging peers. The findings suggest potential investment opportunities despite past strong performance.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Go toTop